FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000875685> ?p ?o ?g. }

• W2000875685 endingPage "2270" @default.
• W2000875685 startingPage "2263" @default.
• W2000875685 abstract "For rare cancers such as neuroendocrine bladder cancer treatment options are limited due partly to the lack of preclinical models. Techniques to amplify rare primary neuroendocrine bladder cancer cells could provide novel tools for the discovery of drug and diagnostic targets. We developed preclinical experimental models for neuroendocrine bladder cancer.Fresh tumor tissue from 2 patients with neuroendocrine bladder cancer was used to establish in vitro and in vivo models. We analyzed additional archived tissues in the National Center of Tumor Diseases tissue bank from patients with neuroendocrine bladder cancer. Primary tumor samples were collected during radical cystectomy. PHA-665752 was used to inhibit MET in animal models and cell cultures. The expression of markers and drug targets in neuroendocrine bladder cancer was determined by flow cytometry. The growth of neuroendocrine bladder cancer in vitro was determined by counting live cells. Tumor growth in mice was assessed by measuring tumor volume. Groups were compared using the nonparametric Kruskal-Wallis test.Xenograft models and serum-free cultures of neuroendocrine bladder cancer cells allowed screening for cell surface markers and drug targets. We found expression of the HGF receptor MET in neuroendocrine bladder cancer cultures, xenograft models and primary patient sections. The growth of neuroendocrine bladder cancer spheroids in vitro depended critically on HGF. Treatment of neuroendocrine bladder cancer bearing mice with a MET inhibitor significantly decreased tumor growth compared to that in control treated mice.Neuroendocrine bladder cancer xenografts and serum-free cultures provided suitable models in which to identify diagnostic markers and therapeutic targets. Using the models, we noted HGF dependent growth of human neuroendocrine bladder cancer and identified MET as a new treatment target for neuroendocrine bladder cancer." @default.
• W2000875685 created "2016-06-24" @default.
• W2000875685 creator A5001598846 @default.
• W2000875685 creator A5003368010 @default.
• W2000875685 creator A5020594033 @default.
• W2000875685 creator A5022650599 @default.
• W2000875685 creator A5036936064 @default.
• W2000875685 creator A5046084721 @default.
• W2000875685 creator A5073901509 @default.
• W2000875685 creator A5081577791 @default.
• W2000875685 creator A5084159957 @default.
• W2000875685 date "2013-12-01" @default.
• W2000875685 modified "2023-09-26" @default.
• W2000875685 title "Development and Characteristics of Preclinical Experimental Models for the Research of Rare Neuroendocrine Bladder Cancer" @default.
• W2000875685 cites W131497487 @default.
• W2000875685 cites W1859579038 @default.
• W2000875685 cites W1971226003 @default.
• W2000875685 cites W1976771782 @default.
• W2000875685 cites W1985264867 @default.
• W2000875685 cites W1996100166 @default.
• W2000875685 cites W1997762751 @default.
• W2000875685 cites W2018360235 @default.
• W2000875685 cites W2019264784 @default.
• W2000875685 cites W2020131167 @default.
• W2000875685 cites W2023427658 @default.
• W2000875685 cites W2026490757 @default.
• W2000875685 cites W2027800847 @default.
• W2000875685 cites W2031919949 @default.
• W2000875685 cites W2038723730 @default.
• W2000875685 cites W2052234466 @default.
• W2000875685 cites W2052859243 @default.
• W2000875685 cites W2057234572 @default.
• W2000875685 cites W2066646758 @default.
• W2000875685 cites W2066757772 @default.
• W2000875685 cites W2081314682 @default.
• W2000875685 cites W2087128761 @default.
• W2000875685 cites W2092335849 @default.
• W2000875685 cites W2097845786 @default.
• W2000875685 cites W2102085111 @default.
• W2000875685 cites W2103746815 @default.
• W2000875685 cites W2108973415 @default.
• W2000875685 cites W2135231064 @default.
• W2000875685 cites W2147081799 @default.
• W2000875685 cites W2156381851 @default.
• W2000875685 cites W4243594247 @default.
• W2000875685 doi "https://doi.org/10.1016/j.juro.2013.06.053" @default.
• W2000875685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23820058" @default.
• W2000875685 hasPublicationYear "2013" @default.
• W2000875685 type Work @default.
• W2000875685 sameAs 2000875685 @default.
• W2000875685 citedByCount "14" @default.
• W2000875685 countsByYear W20008756852013 @default.
• W2000875685 countsByYear W20008756852014 @default.
• W2000875685 countsByYear W20008756852015 @default.
• W2000875685 countsByYear W20008756852016 @default.
• W2000875685 countsByYear W20008756852017 @default.
• W2000875685 countsByYear W20008756852019 @default.
• W2000875685 countsByYear W20008756852020 @default.
• W2000875685 countsByYear W20008756852022 @default.
• W2000875685 crossrefType "journal-article" @default.
• W2000875685 hasAuthorship W2000875685A5001598846 @default.
• W2000875685 hasAuthorship W2000875685A5003368010 @default.
• W2000875685 hasAuthorship W2000875685A5020594033 @default.
• W2000875685 hasAuthorship W2000875685A5022650599 @default.
• W2000875685 hasAuthorship W2000875685A5036936064 @default.
• W2000875685 hasAuthorship W2000875685A5046084721 @default.
• W2000875685 hasAuthorship W2000875685A5073901509 @default.
• W2000875685 hasAuthorship W2000875685A5081577791 @default.
• W2000875685 hasAuthorship W2000875685A5084159957 @default.
• W2000875685 hasConcept C121608353 @default.
• W2000875685 hasConcept C126322002 @default.
• W2000875685 hasConcept C142724271 @default.
• W2000875685 hasConcept C143998085 @default.
• W2000875685 hasConcept C150903083 @default.
• W2000875685 hasConcept C207001950 @default.
• W2000875685 hasConcept C2775910329 @default.
• W2000875685 hasConcept C2779066768 @default.
• W2000875685 hasConcept C2780192828 @default.
• W2000875685 hasConcept C2780341458 @default.
• W2000875685 hasConcept C2780352672 @default.
• W2000875685 hasConcept C502942594 @default.
• W2000875685 hasConcept C71924100 @default.
• W2000875685 hasConcept C86803240 @default.
• W2000875685 hasConceptScore W2000875685C121608353 @default.
• W2000875685 hasConceptScore W2000875685C126322002 @default.
• W2000875685 hasConceptScore W2000875685C142724271 @default.
• W2000875685 hasConceptScore W2000875685C143998085 @default.
• W2000875685 hasConceptScore W2000875685C150903083 @default.
• W2000875685 hasConceptScore W2000875685C207001950 @default.
• W2000875685 hasConceptScore W2000875685C2775910329 @default.
• W2000875685 hasConceptScore W2000875685C2779066768 @default.
• W2000875685 hasConceptScore W2000875685C2780192828 @default.
• W2000875685 hasConceptScore W2000875685C2780341458 @default.
• W2000875685 hasConceptScore W2000875685C2780352672 @default.
• W2000875685 hasConceptScore W2000875685C502942594 @default.
• W2000875685 hasConceptScore W2000875685C71924100 @default.
• W2000875685 hasConceptScore W2000875685C86803240 @default.
• W2000875685 hasIssue "6" @default.

• next